Business Description
Xilio Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US98422T1007
Description
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.58 | |||||
| Equity-to-Asset | 0.6 | |||||
| Debt-to-Equity | 0.34 | |||||
| Debt-to-EBITDA | -0.16 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 1/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -11.9 | |||||
| 3-Year EPS without NRI Growth Rate | -10.3 | |||||
| 3-Year FCF Growth Rate | -20.5 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 44.59 | |||||
| 9-Day RSI | 46.67 | |||||
| 14-Day RSI | 49.94 | |||||
| 6-1 Month Momentum % | -68.3 | |||||
| 12-1 Month Momentum % | -79.46 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.02 | |||||
| Quick Ratio | 3.02 | |||||
| Cash Ratio | 2.8 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.2 | |||||
| Shareholder Yield % | 12.66 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -110.05 | |||||
| ROA % | -79.29 | |||||
| ROIC % | -382.97 | |||||
| ROC (Joel Greenblatt) % | -654.94 | |||||
| ROCE % | -100.09 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.82 | |||||
| Price-to-Tangible-Book | 0.82 | |||||
| EV-to-EBIT | -0.06 | |||||
| EV-to-EBITDA | -0.07 | |||||
| EV-to-FCF | -0.07 | |||||
| Price-to-Net-Current-Asset-Value | 1.25 | |||||
| Price-to-Net-Cash | 1.45 | |||||
| Earnings Yield (Greenblatt) % | -1666.67 | |||||
| FCF Yield % | -171.76 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:XLO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Xilio Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -2.78 | ||
| Beta | 0 | ||
| Volatility % | 99.12 | ||
| 14-Day RSI | 49.94 | ||
| 14-Day ATR ($) | 0.15756 | ||
| 20-Day SMA ($) | 1.2425 | ||
| 12-1 Month Momentum % | -79.46 | ||
| 52-Week Range ($) | 0.49 - 3.4 | ||
| Shares Outstanding (Mil) | 36.91 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Xilio Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Xilio Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Xilio Therapeutics Inc Frequently Asked Questions
What is Xilio Therapeutics Inc(XLO)'s stock price today?
The current price of XLO is $1.09. The 52 week high of XLO is $3.40 and 52 week low is $0.49.
When is next earnings date of Xilio Therapeutics Inc(XLO)?
The next earnings date of Xilio Therapeutics Inc(XLO) is 2024-05-09 Est..
Does Xilio Therapeutics Inc(XLO) pay dividends? If so, how much?
Xilio Therapeutics Inc(XLO) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers